Background: Recent studies indicate an increased incidence of pertussis disease in recent years. The aim of this study was to evaluate the efficacy of the acellular vaccine for children (as a replacement of current whole cell vaccine in the Expanded Program on Immunization) and for high-risk adults in Iran through updating current best available evidence.   Methods: We performed a syste...

background: recent studies indicate an increased incidence of pertussis disease in recent years. the aim of this study was to evaluate the efficacy of the acellular vaccine for children (as a replacement of current whole cell vaccine in the expanded program on immunization) and for high-risk adults in iran through updating current best available evidence.   methods: we performed a systematic li...

The population-level safety benefits of the acellular pertussis vaccine may have been underestimated because only specific adverse events were considered, not overall impact on health services utilization. Using the Vaccine and Immunization Surveillance in Ontario (VISION) system, the authors analyzed data on 567,378 children born between April 1994 and March 1996 (before introduction of acellu...

Background: Recent studies indicate an increased incidence of pertussis disease in recent years. The aim of this study was to evaluate the efficacy of the acellular vaccine for children (as a replacement of current whole cell vaccine in the Expanded Program on Immunization) and for high-risk adults in Iran through updating current best available evidence. Methods: We performed a systematic lite...

In this article we discuss the following: (1) acellular vaccines are immunogenic, but responses vary by vaccine; (2) pertussis antibody levels rapidly wane but promptly increase after vaccination; (3) whole-cell vaccines vary in immunogenicity and efficacy; (4) whole-cell vaccines and naturally occurring pertussis generate predominantly T-helper 1 (Th1) responses, whereas acellular vaccines gen...

OBJECTIVE To provide a review of pertussis vaccines, including information on efficacy, adverse reactions, and antibody production following administration of both whole-cell and acellular pertussis vaccines. DATA SOURCES A MEDLINE search and extensive review of journals was conducted to identify the information for this review. DATA EXTRACTION Pertinent studies reporting experience with pe...

BACKGROUND Because of concern about safety and efficacy, no pertussis vaccine has been included in the vaccination program in Sweden since 1979. To provide data that might permit the reintroduction of a pertussis vaccine, we conducted a placebo-controlled trial of two acellular and one whole-cell pertussis vaccines. METHODS After informed consent was obtained, 9829 children born in 1992 were ...

DESCRIPTION Tripedia®, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP), for intramuscular use, is a sterile preparation of diphtheria and tetanus toxoids adsorbed, with acellular pertussis vaccine in an isotonic sodium chloride solution containing sodium phosphate to control pH. After shaking, the vaccine is a homogeneous white suspension. Tripedia vaccine is dist...

and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliovirus Vaccine) Compared to DAPTACEL 1 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL 1 (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age Michael Smith, MD; Xiaohua Sheng, PhD; Emilia Jordanov, MD; Peter Tsang, MD PhD; Louisville University, Louisville, KY; Cli...

TO THE EDITOR—Kiraly and coauthors recently commented [1] that confounding by age might explain the apparent reduced risk of pertussis described by Witt et al [2] among persons vaccinated with a whole-cell pertussis vaccine (wP) compared to recipients of acellular pertussis vaccine (aP). We note that Table 3 of the original article [2] provides sufficient data to estimate the pertussis attack r...